CONST OF VACCINE CTR: DIABETES TYPE 1

描述（由申请人提供）：本申请向国家研究资源中心（NCRR）寻求资金，以支持正在CHORI建立的CIVD的建设。该中心将包括新的实验室、核心设施和办公空间，适合容纳几个综合科学项目的研究、研究培训和研究支持活动。研究人员将在免疫生物学、传染病、发病机制、疫苗开发和疫苗评价等相互关联的领域进行分子、细胞和临床研究。作为一个整体，CIVD研究人员获得了18项校外奖励，2001年的直接费用总额超过300万美元，其中75%来自美国国立卫生研究院（NIH）。丹·格兰诺夫博士将担任该中心的科学主任。CHORI医学研究副主任Alexander Lucas博士是首席研究员（PI），将负责中心的空间利用和行政管理。CHORI对该项目作出了大量的财政承诺，并在其战略计划中将CIVD指定为高度优先事项。大约8000平方英尺。约1英尺未开发的壳层空间将用作建造CIVD。该中心将提供互动实验室和办公空间，以及专门的共享核心设施，如生物安全3级（BSL3）设施和用于聚合酶链反应（PCR）组装的DNA洁净室。科学发展中心的建设将扩大研究人员的研究能力，促进程序化的互动和发展，增加培训机会，并允许招聘更多的科学家。

DESCRIPTION (provided by applicant): This application seeks funds from the National Center for Research Resources (NCRR) to support construction of the CIVD being established at the CHORI. The Center will consist of new laboratories, core facilities and office spaces suitable to house the research, research training and research support activities of several integrated scientific programs. The investigators who will occupy the Center conduct molecular, cellular and clinical studies in the inter-related areas of immunobiology, infectious diseases, pathogenesis, vaccine development and vaccine evaluation. As a group, the CIVD investigators have 18 extramural awards with total direct costs in year 2001 that exceed $3 million of which 75 percent derives from the National Institutes of Health (NIH). Dr. Dan Granoff will be the Scientific Director of the Center. Dr. Alexander Lucas, Deputy Director of Medical Research at CHORI, is the Principal Investigator (PI) and will be responsible for the space utilization and the administrative management of the Center. CHORI has made a substantial financial commitment to this project and has designated the CIVD as a high priority in its Strategic Plan. Approximately 8,000 sq. ft. of undeveloped shell space will be used for construction of the CIVD. The Center will provide interactive laboratory and office spaces as well as specialized shared core facilities, such as a Biosafety Level 3 (BSL3) facility and a DNA clean room for polymerase chain reaction (PCR) assembly. Construction of the CIVD will expand investigators' research capabilities, promote programmatic interaction and growth, increase training opportunities, and permit recruitment of additional scientists.